Mark Ellis, MD
Pediatric Allergy/Immunology · Orange, CANPI 1568569424
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 397 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,551 and has fallen 65.8% since, to $872 in 2025.
Across 397 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Sanofi$1K
- Takeda Pharmaceuticals U.S.A., Inc.$923
- AstraZeneca$672
- Pfizer$444
- plus $3K from 22 others
Across 13 payments — averaging $2522.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$18K
- Regeneron$15K
What the payments were for
- Food & beverage$8,52598%
- Education$1942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 60 | $1,558 |
| Regeneron Healthcare Solutions, Inc. | 58 | $1,513 |
| Sanofi | 75 | $1,026 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $923 |
| AstraZeneca | 30 | $672 |
| Pfizer | 17 | $444 |
| GSK | 17 | $392 |
| Genentech USA, Inc. | 11 | $364 |
| Amgen(2 entities) | 12 | $346 |
| Shire North American Group Inc | 11 | $223 |
| Novartis | 10 | $166 |
| Optinose US, Inc. | 9 | $163 |
| Sanofi-aventis U.S. LLC | 2 | $119 |
| Pharming Healthcare, Inc. | 2 | $112 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $96 |
| Incyte Corporation | 3 | $87 |
| Kaleo, Inc. | 3 | $63 |
| AbbVie | 2 | $60 |
| Teva Pharmaceuticals USA, Inc. | 3 | $58 |
| Octapharma USA, Inc. | 2 | $53 |
| Grifols USA, LLC | 3 | $52 |
| Biocryst US Sales Co., LLC | 2 | $45 |
| LEO Pharma Inc. | 2 | $43 |
| Boehringer Ingelheim | 2 | $36 |
| Ionis Pharmaceuticals, Inc. | 1 | $34 |
| Azurity Pharmaceuticals, Inc. | 1 | $28 |
| Organon | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,719 in reported general payments places this provider in the 70th percentile of 48 pediatric allergy/immunology providers in California.
See all pediatric allergy/immunology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 16 | $65,686 |
| Dupixent SyringeDupilumab | 14 | $61,175 |
| XolairOmalizumab | 16 | $33,384 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $11,084 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $8,010 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,499 |
| BreynaBudesonide/Formoterol Fumarate | 16 | $2,483 |
| Budesonide | 12 | $2,413 |
| Wixela InhubFluticasone Propion/Salmeterol | 32 | $2,137 |
| Azelastine Hcl | 56 | $1,624 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $1,293 |
| Fluticasone Propionate | 52 | $1,088 |
| Montelukast Sodium | 116 | $1,082 |
| Levocetirizine Dihydrochloride | 12 | $152 |
| Prednisone | 17 | $114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $392 | $8,01015 claims |
| AstraZenecaSymbicort | $672 | $4,49916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 48 pediatric allergy/immunology providers in California.
Other pediatric allergy/immunology in Orange
- Manish ButteLos Angeles$357K
- Barbara AriueSan Bernardino$112K
- Peck OngLos Angeles$83K
- Christopher LandonVentura$60K
- Brian GreenbergTarzana$45K
- Alejandro Dorenbaum-KracerPalo Alto$42K
- Maria Garcia-LloretLos Angeles$39K
- Talal ChatilaLos Angeles$30K
- Morna DorseySan Francisco$29K
- Ewald StiehmLos Angeles$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.